Urology

A cohort study found longer overall survival with androgen receptor inhibitors than androgen synthesis inhibitors among patients with metastatic hormone-sensitive prostate cancer.

Local treatment was linked to fewer years of life lost in intermediate-risk prostate cancer, particularly among younger patients.

Kidney stone prevention knowledge gaps were identified among 405 Sudanese healthcare providers.

A nationwide cohort study found that longer denosumab treatment was associated with increased osteonecrosis of the jaw risk but no additional reduction in skeletal events beyond 12 months.

Treatment-emergent skin toxic effects during first-line enfortumab vedotin plus pembrolizumab were associated with longer overall survival.

Researchers developed an oxidative stress-based model to predict biochemical recurrence in prostate cancer and identified LAMP5 as a candidate prognostic biomarker.

A single-centre study found that elevated prostate-specific antigen density and perineural invasion were independently associated with Gleason score upgrading after radical prostatectomy in men initially diagnosed with Gleason 6 prostate cancer.

ERBB2-positive bladder cancer showed a 73.1% complete response rate with combination therapy in a phase II trial.